Overview

Study of SOR007 Ointment for Actinic Keratosis

Status:
Completed
Trial end date:
2018-03-12
Target enrollment:
Participant gender:
Summary
A Phase 2, randomized, double-blind, dose rising study to determine the safety, tolerability, and preliminary efficacy of four concentrations of SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment (SOR007) compared to SOR007 ointment vehicle applied to actinic keratosis (AK) lesions on the face twice daily for up to 28 days.
Phase:
Phase 2
Details
Lead Sponsor:
DFB Soria, LLC
Collaborator:
US Biotest, Inc.
Treatments:
Paclitaxel